Effects of cetuximab and gefitinib treatment on the levels of total and phosphorylated EGFR and EGFR substrates in cell lines with wild-type and mutated EGFR

<p><b>Copyright information:</b></p><p>Taken from "Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1α"</p><p>http://www.molecular-cancer.com/content/6/1/63</p><p>Molecular Cancer 2007;6():63-63.</p><p>Published online 11 Oct 2007</p><p>PMCID:PMC2117021.</p><p></p> Cells from the indicated lines were simultaneously switched to a culture medium containing 0.5% FBS and were either left untreated or treated with cetuximab (2 and 10 nM), vehicle, or gefitinib (0.1 and 0.5 μM) overnight (16 hours). A master medium containing either cetuximab or gefitinib was used in all cell lines. After treatment, the cells were lysed, and equal amounts of cell lysates were subjected to Western blot analysis using antibodies directed against total and phosphorylated EGFR (Y-1068) () and antibodies directed against phosphorylated ERK, Akt, and STAT3 as indicated (). The levels of β-actin and total ERK served as internal controls for equal protein loading in each lane in () and (), respectively. The numeric values under each gel were derived from a densitometric analysis of the signals